IRulya Therapeutics Inc. Common Stock
IRLA
63 hedge funds and large institutions have $523M invested in IRulya Therapeutics Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
26% more funds holding
Funds holding: 50 → 63 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.49% less ownership
Funds ownership: 39.43% → 38.95% (-0.49%)
12% less capital invested
Capital invested by funds: $594M → $523M (-$71.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.2M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$8.44M |
| 3 |
PHAM
Pacific Heights Asset Management
San Francisco,
California
|
+$5.68M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$4.87M |
| 5 |
BlackRock
New York
|
+$3.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.86M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$3.26M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.26M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$681K |
| 5 |
Goldman Sachs
New York
|
-$443K |
IRLA Hedge Fund Activity: Q1 2020 in Review
63 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q1 2020, worth a combined $523M — down 12% from $594M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new IRLA positions and 2 closed out — a net gain of 13 holders — while 26 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $12.2M. The largest seller was Morgan Stanley, cutting an estimated $3.86M.
- 63 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q1 2020, up from 50 in Q4 2019.
- Funds reported $523M of IRulya Therapeutics Inc. Common Stock stock for Q1 2020, down 12% quarter-over-quarter.
- 15 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +13 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q1 2020 was Citadel Advisors, an estimated $12.2M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q1 2020 was Morgan Stanley, an estimated $3.86M sold.
Based on aggregated 13F filings for Q1 2020.